MEDI-SECURE: A SPECIFIC **DEVELOPMENT APPROACH**

BIODERMA LABORATOIRE DERMATOLOGIOUE

BIODERA

* MEDI-SECURE development approach

Carefully selected ingredients and active ingredients that are recognised by health professionals to quarantee optimum safety

Practical and hygienic packaging to facilitate use and improve daily life







Guaranteed results backed by clinical studies under medical and oncological supervision

NEW

2 NEW **MEDI-SECURE PRODUCTS** TO PRESERVE SKIN WEAKENED BY TREATMENTS OR PATHOLOGIES

> **MEDI-SECURE** APPROACH

> > BIODERMA ODERMA

Sensibio Erycontrol

Crème apaisante hydratante

Accompagnement dermo-cosmétique des peaux sujettes aux sensibilités et rougeurs superficielles induites par certains traitements notamment anticancéreux

Soothing moisturising cream Dermo-cosmetic care for skin prone to sensitivity and superficial redness caused by certain treatments. particularly cancer treatments

Care first. X N A O S

100 ml € 3.4 FL.OZ.

Atoderm Palmakera

Soin lissant apaisant

Accompagnement dermo-cosmétique des mains et des pieds sujets aux desquamations et sensations d'inconfort notamment induites par certains traitements anticancéreux ou par le diabète

Smoothing soothing care

Dermo-cosmetic care for hands and feet prone to desquamation and feelings of discomfort, particularly caused by certain cancer treatments or by diabetes

Care first. X N A O S

100 ml ⊖ 3.4 FL.OZ.



Learn more about NAOS, French ecobiology company, founder of BIODERMA, on www.naos.com



VAOS, SAS with a capital of £ 43,474,650, R.C. S. Aix-en-Provence B535 236 418, 355 rue Pierre-Simon Laplace 13290 Aix-en-Provence. BD-CC (0126) February 2021





ADAPTED DERMO-COSMETIC CARE FOR EVERY SKIN

Dryness

Atoderm Xereane

Soothing nourishing dermo-cosmetic balm for skin dried by some treatments or pathologies

✓ CHEMOTHERAPY

cancer patients(1)

✓ DIABETES

✓ DIALYSIS

71% under dialysis⁽³⁾

SCALING IMPROVEMENT AFTER 28 DAYS



150 ml

Apply once or twice a day to face and/or body after cleansing

INGREDIENTS: AQUA/WATER/EAU, GLYCERIN, BUTYROSPERMUM PARKII (SHEA) OIL, BUTYLENE GLYCOL, PANTHENOL, JOJOBA ESTERS, BEHENYL ALCOHOL, HYDROGENATED CASTOR OIL, SQUALANE, SUCROSE STEARATE, HELIANTHUS ANNUUS SUCROSE STEARATE, HELIANTHUS ANNOUS (SUNFLOWER) SEED WAX, PENTYLENE GLYCOL, SODIUMCITRATE, SUCROSE LAURATE, SODIUM POLYACRYLATE, CITRIC ACID, 1,2-HEXANEDIOL, CAPRYLYLGLYCOL, POLYACRYLATE CROSSPOLYMER-6, XANTHAN GUM, POLYGLYCERIN-3, MANNITOL, XYLITOL, RHAMNOSE, ACACIA DECURRENS FLOWER WAX, ACETYL DIPEPTIDE-1 CETYL ESTER. [BI 755]

Hands and feet prone to desquamation and feelings of discomfort

Atoderm Palmakera

Smoothing soothing dermo-cosmetic care for hands and feet prone to desquamation and feelings of discomfort caused by certain cancer treatments or by diabetes

✓ CHEMOTHERAPY

skin smoothed

✓ DIABETES

Foot thickening limited + skin very hydrated(5)

NEW



Apply at least twice a day to affected areas after cleansing with a gentle hygiene product.

INGREDIENTS: AQUA/WATER/EAU, UREA, GLYCERIN, CAPRYLIC/CAPRIC TRIGLYCERIDE, DIPROPYLENE GLYCOL, BUTYLENE GLYCOL, BEHENYL ALCOHOL GLYCERYL STEARATE CITRATE, MANGIFERA INDICA (MANGO) SEED BUTTER, SUCROSE STEARATE, ISOSTEARYL ISOSTEARATE, SODIUM LACTATE, XANTHAN GUM, GLYCYRRHETINIC ACID, PENTYLENE GLYCOL, LACTIC ACID, 1,2-HEXANEDIOL, CAPRYLYL GLYCOL, MANNITOL, XYLITOL, SODIUM HYDROXIDE, RHAMNOSE, ACETYL DIPEPTIDE-1 CETYLESTER. [B1746]

Superficial skin irritation and scars

Cicabio Restor

Protective soothing dermo-cosmetic care for skin weakened by some cancer treatments

♥ CHEMOTHERAPY

✓ RADIOTHERAPY

✓ SURGERY

superficial skin irritation (6) Skin prone to sensitivity and superficial redness

Sensibio **Erycontrol**

Moisturising soothing dermo-cosmetic cream for skin prone to sensitivity and superficial redness caused by cancer treatments

✓ CHEMOTHERAPY

no superficial redness⁽⁷⁾



Apply once or twice day to affected areas after cleasing with a gentle hygiene product.

INGREDIENTS: AQUA/WATER/EAU, BUTYROSPERMUM PARKII (SHEA) OIL, GLYCERIN, PANTHENOL, BUTYLENE GLYCOL, BEHENYL ALCOHOL, HYDROGENATED CASTOR OIL, PROPANEDIOL, JOJOBA ESTERS, CAPRYLOYL GLYCINE, SOLIAI ANE SUCROSE STEARATE HELIANTHUS ANNUUS (SUNFLOWER) SEED WAX, PENTYLENE GLYCOL, SODIUM CITRATE, SUCROSE LAURATE, SODIUM POLYACRYLATE POLYACRYLATECROSSPOLYMER-6, XANTHAN GUM SODIUM HYDROXIDE, POLYGLYCERIN-3, MANNITOL, SODIUM HYALURONATE. XYLITOL RHAMNOSE. ACETYL DIPEPTIDE-1 CETYLESTER ACACIA DECLIRRENS ELOWER WAX. IBI 744



NEW

100 m

Apply twice a day to affected areas after cleansing with a gentle hygiene product.

INGREDIENTS: AQUA/WATER/EAU, CAPRYLIC/ CAPRICTRIGLYCERIDE, GLYCERIN, BUTYLENE GLYCOL, DIPROPYLENE GLYCOL, C10-18 TRIGLYCERIDES, GLYCERYL STEARATE CITRATE, MANGIFERA INDICA (MANGO) SEED BUTTER, SUCROSE STEARATE GLYCYRRHETINIC ACID, PENTYLENE GLYCOL, SODIUM POLYACRYLATE, 1,2-HEXANEDIOL, CAPRYLYL GLYCOL, CITRIC ACID, SODIUM CITRATE, XANTHAN GUM, MANNITOL, XYLITOL, RHAMNOSE, ACETYL DIPEPTIDE-1 CETYL ESTER, [BI745]

(1) An observational, prospective and multicentric study with 2 visits (D0, D28). 40 subjects with chemotherapy Induced sensit was, project by 9 investigating oncologists, 2019; (2) A prospective monocentric observational with 2 visit (p.0, 28) involving 40 subjects with diabetic sensits included by one dermatical study of the visit (p.0, 28) involving 40 subjects with diabetic sensits included by one dermatical situation of the visit (p.0, 28) involving 32 subjects with renal diabysis-induced sensits included by one dermatical situation of the prevention of the prevention of the provention of the prove included by 5 oncologists, 2020. (5) A prospective monocentric observational intra-individual study on the prevention of cutaneous complications of diabetic feet, with 2 visits (D0, D28), involving 30 subjects included by 1 dermatologist, 2019. (6) A prospective, multicentric observational study with three visits (D0, D7 and D28) involving 34 subjects with grade II hand foot syndrome included by eight oncologists, 2019. (7) Multicentric observational prospective phase III study to support acneiform skin lesions induced by anti tumoral treatments, with 5 visits (D0, D14, D28, D42, D56), involving 36 subjects, included by 5 oncologists, 2019.